Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 250-255

  Abbas, Sascha ^a   Chang Claude, Jenny ^a   Linseisen, Jakob ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

25 Hydroxyvitamin D; Breast cancer; Case control study; Epidemiology; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; PROGESTERONE RECEPTOR; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; VITAMIN BLOOD LEVEL; BLOOD; BREAST TUMOR; MIDDLE AGED; REGRESSION ANALYSIS; RISK; RISK FACTOR; SOCIAL CLASS;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GERMANY; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; ODDS RATIO; PREMENOPAUSE; QUESTIONNAIRES; REGRESSION ANALYSIS; RISK FACTORS; SOCIAL CLASS; VITAMIN D;

EID: 58149402917     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23904     Document Type: Article

References (53)

1. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006;102:156-162.
2. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocrine Relat Cancer 2002;9:45-59.
3. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003;88:695-705.
4. Eisman JA, Maclntyre I, Martin TJ, Frampton RJ, King RJ. Normal and malignant breast tissue is a target organ for 1,25-(0H)2 vitamin D3. Clin Endocrinol (Oxford) 1980;13:267-272.
5. Saez S, Falette N, Guillot C, Meggouh F, Lefebvre MF, Crepin M. William L. McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat 1993;27:69-81.
6. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:519-26.
7. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 2002;94:1301-11.
8. McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, Thun MJ, Calle EE. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2898-904.
9. Witte JS, Ursin G, Siemiatycki J, Thompson WD, Paganini-Hill A, Haile RW. Diet and premenopausal bilateral breast cancer: a case-control study. Breast Cancer Res Treat 1997;42:243-51.
10. Potischman N, Swanson CA, Coates RJ, Gammon MD, Brogan DR, Curtin J, Brinton LA. Intake of food groups and associated micronu-trients in relation to risk of early-stage breast cancer. Int J Cancer 1999;82:315-21.
11. Levi F, Pasche C, Lucchini F, La Vecchia C. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer 2001;91:260-3.
12. Simard A, Vobecky J, Vobecky JS. Vitamin D deficiency and cancer of the breast: an unprovocative ecological hypothesis. Can J Public Health 1991;82:300-3.
13. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a german case-control study. Nutr Cancer 2007;59:54-61.
14. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control 2007;18:775-82.
15. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Int Med 2007;167:1050-9.
16. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999;8:399-406.
17. John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Breast Cancer Risk in a Multiethnic Population. Am J Epidemiol 2007;166:1409-19.
18. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 2003;164:239-46.
19. Welsh JE, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003;133:2425S-33S.
20. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86:888-94.
21. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008;29:93-9.
22. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2008;17:889-94.
23. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005;41:1164-9.
24. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d and risk of breast cancer. Cancer Epidemiol Bio-markers Prev 2005;14:1991-7.
25. Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 1999;2:283-91.
26. Bertone-Johnson ER. Prospective studies of dietary vitamin D and breast cancer: more questions raised than answered. Nutr Rev 2007; 65:459-66.
27. Chang-Claude J, Eby N, Kiechle M, Bastert G, Becher H. Breastfeeding and breast cancer risk by age 50 among women in Germany. Cancer Causes Control 2000;11:687-95.
28. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-74.
29. Rowling MJ, Kemmis CM, Taffany DA, Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxy-cholecalciferol actions in human mammary cells. J Nutr 2006;136: 2754-9.
30. Kemmis CM, Salvador SM, Smith KM, Welsh J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 2006;136:887-92.
31. Hansen CM, Binderup L, Hamberg KJ, Carlberg C Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 2001;6:D820-D48.
32. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 2003;80:49-62.
33. Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Oren-treich N. Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst 1998;90:461-63.
34. Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Res 2006;66:588-97.
35. Xie SP, James SY, Colston KW. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997;154:495-504.
36. Bell NH. Vitamin D metabolism, aging, and bone loss. J Clin Endocrinol Metab 1995;80:1051.
37. James SY, Mackay AG, Binderup L, Colston KW. Effects of a new synthetic vitamin D analogue. EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 1994;141:555-63.
38. Swami S, Krishnan AV, Feldman D. 1 alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 2000;6:3371-9.
39. Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5. Carcino-genesis 2007;28:1000-7.
40. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 2003;84:181-192.
41. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55:2822-30.
42. Holick MF. Vitamin D: biosynthesis, metabolism, and mode of action. In: DeGroot LJ, Cahill GF Jr, Martini L, Nelson DH, Odell WD, Potts JT, Jr, Steinberger E, Winegrad AI, eds. Endocrinology. New York: Grune and Stratton, 1989. 902-26.
43. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, Giovannucci EL. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-8.
44. Mehta R, Hawthorne M, Uselding L, Albinescu D, Moriarty R, Christov K, Mehta R. Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5). J Natl Cancer Inst 2000;92:1836-40.
45. Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst 1997;89:212-8.
46. VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog. EB1089. Endocrinology 1998;139:2102-10.
47. Kailajarvi ME, Salminen EK, Paija OM, Virtanent AM, Leino AE, Irjala KA. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anti-cancer Res 2004;24:1271-4.
48. Gao Y, Shimizu M, Yamada S, Ozaki Y, Aso T. The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocrinol J 1993;40:737-42.
49. Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2007 May 30; Epub ahead of print.
50. Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004;89:3152-7.
51. Hollis BW. Editorial: The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 2004;89:3149-51.
52. Zerwekh JE. The measurement of vitamin D: analytical aspects. Ann Clin Biochem 2004;41:272-81.
53. Carter GD, Carter R, Jones J, Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 2004;50:2195-7.